Immunic Inc. Announces New Stock Appreciation Rights Plan for Employees and Executives, Pending Shareholder Approval
Immunic Inc. has announced a new compensation plan authorized by its Board of Directors on July 7, 2025, involving the issuance of up to 35,000,000 stock appreciation rights (SARs) to its employees and executive officers. Of this total, 22,015,000 SARs are allocated to executive officers. The SARs, intended to be settled in shares of the company's common stock, are contingent upon stockholder approval to amend the 2019 Omnibus Equity Incentive Plan to accommodate the necessary number of shares. The exercise price for each SAR is set at $0.77, the closing price of the stock on the authorization date. The SARs become exercisable from August 1, 2026, with specific conditions tied to the exercise of the company's series A and B purchase warrants and the issuance of stock or warrants in relation to the company's January 2024 private placement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001008), on July 11, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。